Palvella Therapeutics (PVLA) Cash & Current Investments (2013 - 2026)
Palvella Therapeutics (PVLA) reported Cash & Current Investments of $261.9 million for Q1 2026, up 246.25% year-over-year from $75.6 million in Q1 2025, and up 351.61% quarter-over-quarter from $58.0 million in Q4 2025.
Palvella Therapeutics (PVLA) Cash & Current Investments (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has 14 years of Cash & Current Investments data on file, last reported at $261.9 million in Q1 2026.
- Cash & Current Investments for Q1 2026 came in at $261.9 million, up 246.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $261.9 million (up 246.25% YoY), and the FY2025 annual result was $58.0 million, down 30.65% from the prior year.
- Cash & Current Investments grew to $261.9 million in Q1 2026 per PVLA's latest filing, from $58.0 million in the prior quarter.
- Over five years, Cash & Current Investments peaked at $261.9 million in Q1 2026 and troughed at $6.2 million in Q1 2024.
- A 5-year average of $67.3 million and a median of $63.6 million in 2025 frame the typical range for Cash & Current Investments.
- The sharpest annual moves came in 2024 and 2025: Cash & Current Investments plunged 87.09% in 2024, then jumped 1110.4% in 2025.
- A 5-year view of Cash & Current Investments shows it stood at $59.2 million in 2022, then plunged by 72.42% to $16.3 million in 2023, then jumped by 412.27% to $83.6 million in 2024, then sank by 30.65% to $58.0 million in 2025, then jumped by 351.61% to $261.9 million in 2026.
- Business Quant data shows PVLA's Cash & Current Investments at $261.9 million in Q1 2026, $58.0 million in Q4 2025, and $63.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.13 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 7.20 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 7.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Palvella Therapeutics | 1.49 Bn | 1.23 Bn | - | 261.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 261.85 Mn |
| Dec 31, 2025 | 57.98 Mn |
| Sep 30, 2025 | 63.57 Mn |
| Jun 30, 2025 | 70.43 Mn |
| Mar 31, 2025 | 75.63 Mn |
| Dec 31, 2024 | 83.60 Mn |
| Sep 30, 2024 | 14.21 Mn |
| Jun 30, 2024 | 14.54 Mn |
| Mar 31, 2024 | 6.25 Mn |
| Dec 31, 2023 | 16.32 Mn |
| Sep 30, 2023 | 56.72 Mn |
| Jun 30, 2023 | 64.84 Mn |
| Mar 31, 2023 | 48.38 Mn |
| Dec 31, 2022 | 59.17 Mn |
| Sep 30, 2022 | 69.82 Mn |
| Jun 30, 2022 | 80.94 Mn |
| Mar 31, 2022 | 100.27 Mn |
| Dec 31, 2021 | 117.76 Mn |
| Sep 30, 2021 | 34.90 Mn |
| Jun 30, 2021 | 91.80 Mn |